Chain: engineering microbial delivery to the colon

Why Chain thinks its bacterial spore-based platform could help deliver therapies to the colon

Chain Biotechnology’s engineered Clostridium-based therapies that are administered as dose-adjustable bacterial spores could offer more targeted delivery to the colon than other microbial therapies.

“Most microbial activity in the GI tract occurs in the colon,” said Chain Biotechnology Ltd. founder and CEO Edward Green. “This is the organ where the microbiome has the biggest impact on health and disease through the production of molecules that impact the gut barrier and mucosal immune system, resident

Read the full 747 word article

User Sign In